



Novartis India Limited  
Registered Office:  
Inspire BKC  
Part of 601 & 701  
Bandra Kurla Complex  
Bandra (East)  
Mumbai – 400 051  
Maharashtra, India  
Tel +91 22 50243000  
Fax +91 22 50243010  
Email: india.investors@novartis.com  
CIN No. L24200MH1947PLC006104  
Website: www.novartis.in

September 30, 2022

To,  
The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001

Scrip code: 500672

Dear Sir/ Madam,

**Sub.: Intimation of meeting of the Board of Directors of Novartis India Limited (“the Company”) and Closure of Trading Window**

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 9, 2022, to *inter alia*, consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ending on September 30, 2022.

In this connection, please note that pursuant to the ‘Code of Conduct to regulate, monitor and report share trading by Designated Persons and their immediate relatives’ (“Code”) read with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading Window for dealing in shares of the Company by Designated Persons shall remain closed with effect from Saturday, October 1, 2022 to Friday, November 11, 2022 (both days inclusive).

You are requested to kindly take note of the above information.

Thanking You.

Yours Sincerely,

For Novartis India Limited

**Nikhil Malpani**  
Company Secretary and Compliance Officer

